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Graphene family nanomaterials for application in
cancer combination photothermal therapy
Duarte de Melo-Diogo, *†a Rita Lima-Sousa, †a Cátia G. Alves †a and
Ilídio J. Correia *a,b
Combining hyperthermia with other therapies holds a great potential for improving cancer treatment. In
this approach, the increase in the body temperature can exert a therapeutic effect on cells and/or
enhance the effectiveness of anticancer agents. However, the conventional methodologies available to
induce hyperthermia cannot confine a high temperature increase to the tumor-site while maintaining
healthy tissues unexposed and ensuring minimal invasiveness. To overcome these limitations, combi-
nation photothermal therapy (PTT) mediated by graphene family nanomaterials (GFN) has been showing
promising results. Such is owed to the ability of GFN to accumulate at the tumor site and convert near
infrared light into heat, enabling a hyperthermia with a high spatial-temporal resolution. Furthermore,
GFN can also incorporate different therapeutic agents on their structure for delivery purposes to cancer
cells. In this way, the combination PTT mediated by GFN can result in an improved therapeutic effect. In
this review, the combination of GFN mediated PTT with chemo-, photodynamic-, gene-, radio-, and
immuno-therapies is examined. Furthermore, the main parameters that influence these types of combi-
nation approaches are also analyzed, with emphasis on the photothermal potential of GFN and on the
vascular and cellular effects produced by the temperature increase mediated by GFN.
1. Introduction
Combining hyperthermia with radio- or chemo-therapies is a
promising approach to improve cancer treatment.1,2 In these
therapeutic modalities, the increase in the body temperature
(hyperthermia) can exert a therapeutic effect on cells and/or
enhance the effectiveness of the other anticancer agents. In
this way, the outcome of hyperthermia-based combination
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therapies is highly dependent on the maximum temperature
achieved. However, the methodologies available to induce
hyperthermia can limit its full therapeutic potential since
these do not confine a high temperature increase to the
tumor-site while maintaining healthy tissues unexposed and
ensuring a minimal procedure invasiveness.3,4
To overcome these limitations, combination photothermal
therapy (PTT) mediated by nanomaterials is a promising
approach.1,5–9 This type of therapy employs precisely engin-
eered nanostructures that, due to their physicochemical
properties, can achieve a high tumor accumulation.10–13
Subsequently, the tumor zone is irradiated with laser light,
and the nanomaterials’ accumulated in this site interact with
this radiation, producing an on-demand temperature
increase.12,14,15 The use of near infrared (750–1000 nm; NIR)
light in these procedures is fundamental since it has minimal
or insignificant interactions with biological components (e.g.
water, collagen, melanin), thus ensuring a high penetration
depth and minimal off-target heating.5,12,16,17 Furthermore,
these NIR-responsive nanomaterials may also accommodate
other anticancer agents on their structure,18–25 enabling the
pursuit of synergistic therapeutic outcomes.
Among the different types of materials capable of being
efficiently applied in combination PTT, graphene family nano-
materials (GFN) have been showing very promising
results.26–32 Such is owed to the GFN ability to absorb NIR
light and convert it into heat, enabling a PTT with a high
spatial-temporal resolution.33–37 Furthermore, the aromatic
lattice of GFN enables the direct loading of different agents
(e.g. drugs, photosensitizers) on their structure for delivery
purposes to cancer cells.38–41 In this way, combining the
photothermal and delivery capacities of GFN can result in an
improved therapeutic effect.
In this review, the cancer combination PTT mediated by
GFN is analyzed. Firstly, the synthesis and general properties
of GFN are overviewed (section 2). Afterwards, the main para-
meters that influence the combination PTT mediated by GFN
are reviewed (section 3), with emphasis on the photothermal
potential of GFN (section 3.1), and on the vascular and cellular
effects produced by the temperature increase mediated by GFN
(section 3.2). Then, the combination of GFN mediated PTT
with chemotherapy (section 4), photodynamic therapy
(section 5), gene therapy (section 6), radiotherapy (section 7),
and immunotherapy (section 8) is reviewed. Finally, an
outlook about the state of the art and the future directions are
presented in section 9. For the sake of simplicity, this review
will not cover the application of GFN mediated PTT in conju-
gation with other photothermal agents (e.g. gold nanorods-
GFN hybrids) nor with porous nanostructures with loading
capacity (e.g. mesoporous silica-GFN hybrids).
2. GFN: synthesis and general
properties
The members of the GFN are synthesized through different
routes (extensively reviewed in ref. 42–44), originating
materials with distinct properties that influence their appli-
cation in cancer therapy.
Graphene oxide (GO) is commonly explored in photothermal
applications and is also used as a precursor for the preparation
of other GFN.32 This nanomaterial is composed of a monolayer
graphitic lattice incorporating several types of oxygen functional
groups such as hydroxyl, carboxyl or epoxy (Fig. 1). The chemical
oxidation of graphite and exfoliation of the attained material is
the process usually employed to produce GO.45,46 In this regard,
the improved Hummers’ method (uses H2SO4, H3PO4 and
KMnO4 for graphite oxidation) has been widely used to produce
GO due to its high reaction yield.46 The NIR absorption of GO
allows its application in photothermal therapy (discussed in
detail in section 3.1.). Furthermore, the aromatic lattice of this
nanomaterial enables the direct loading of different therapeutic
agents on its structure through hydrophobic–hydrophobic
interactions and/or π–π stacking.38,47–49
GO can also be treated with reducing agents (e.g. hydrazine
hydrate,34,50 L-ascorbic acid,51 glucose52) at 80–95 °C, yielding
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reduced graphene oxide (rGO) (Fig. 1). This treatment intents
to restore the graphitic aromatic lattice by removing the
oxygen-functional groups, resulting in an improvement in the
nanomaterials’ NIR absorption.32,34 When compared to GO,
rGO also presents a higher drug loading capacity,53,54 thereby
being a promising agent for the delivery of therapeutics to
cancer cells.
There are other GFN with a good photothermal potential
but whose application in cancer therapy is not so widespread
since their synthesis is more complex. This group includes
graphene oxide nanoribbons (GONR), reduced graphene oxide
nanoribbons (rGONR) and reduced graphene oxide nanomesh
(rGONM).
GONR are produced through the oxidation of multiwall
carbon nanotubes (using KMnO4 and H2SO4).
55,56 This process
also leads to the unzipping of the nanotubes (Fig. 1).55,56 The
chemical treatment of GONR with reducing agents (e.g. hydra-
zine hydrate) generates rGONR, which also display an
enhanced NIR absorption.55
rGONM is produced through the photodegradation of GO
(using TiO2 nanoparticles immobilized on a SiO2-film and
radiation from a mercury lamp) and subsequent reduction
Fig. 1 Synthesis routes of the members of the GFN.
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(using hydrazine hydrate) of the attained material (Fig. 1).57
The use of rGONM for cancer PTT is also appealing due to its
improved NIR absorption.57
Nevertheless, the as-synthesized GFN present critical limit-
ations that hinder their direct application in cancer therapy.
Even though GO based materials have some water solubility
(due to their oxygen-functional groups), these materials pre-
cipitate in saline solutions and biological fluids.32,34 Several
reports have shown that as-synthesized GO based materials
can present a cytocompatible profile in vitro (which is depen-
dent on multiple factors, such as materials’ physicochemical
properties, impurities, presence of serum).32 However, the
in vivo intravenous administration of GO leads to its accumu-
lation and retention in the lungs, inducing severe effects on
this organ.58 The rGO derivatives display limited water solubi-
lity and also precipitate in biological-relevant media.32,34
Furthermore, rGO derivatives are highly cytotoxic, a fact that
can be attributed to their insolubility and contamination with
traces of hydrazine hydrate (a highly toxic reducing agent used
in the majority of the protocols followed to produce rGO
derivatives).32,52
The limitations of as-synthesized GFN can be surpassed by
functionalizing them with materials (e.g. hydrophilic poly-
mers) capable of enhancing nanostructures’ colloidal stability
and biocompatibility (extensively reviewed by our group in
ref. 32). In this way, the functionalization of GFN enables their
application in cancer therapy.32 For this purpose, the carboxyl
groups of GO based materials can be covalently bond to
primary amine-terminated polymers using the carbodiimide
chemistry.32,34,59 In this regard, Yang et al. demonstrated that
GO derivatives functionalized with amine-terminated
branched poly(ethylene glycol) (PEG) did not induce any tox-
icity to mice when administered by intravenous, intraperito-
neal and oral routes, thus displaying an excellent biocompat-
ibility in vivo.59,60 Similar findings were also observed for GO
functionalized with amine-terminated Dextran.61 On the
other hand, the aromatic lattice of the rGO based materials
can be functionalized with amphiphilic polymers
through hydrophobic-hydrophobic interactions and/or π–π
stacking.32,34,51,55,57 In this regard, rGO functionalized with
PEGylated poly(maleic anhydride-alt-1-octadecene) and bovine
serum albumin also displayed a biocompatibility profile suit-
able for in vivo applications.60,62,63
3. GFN mediated combination PTT
The application of GFN in cancer combination PTT generally
starts with the administration of these nanomaterials through
intravenous injection.62,64–66 After entering into the blood cir-
culation, GFN can accumulate in the tumor zone by taking
advantage from the tumor’s leaky vasculature (enhanced per-
meability and retention (EPR) effect) and from the dynamic
vents that spontaneously occur in the tumor associated
vessels.32,67,68 Subsequently, the tumor zone is exposed to NIR
light and the GFN convert the absorbed radiation into
heat.32,34 In this way, GFN can confine the hyperthermia to
this site and elicit minimal off-target heating.12,32 The attained
temperature increase in the tumor zone can per se induce
damage on cancer cells and/or sensitize them to the action of
other agents, leading to an improved therapeutic outcome.
In this way, the combination PTT mediated by GFN
depends strongly on three factors: (i) the ability of GFN to
reach the tumor zone, (ii) the intrinsic photothermal capacity
of each member of the GFN and (iii) the temperature variation
achieved, upon laser irradiation, at the tumor site.
The ability of GFN to effectively reach the tumor zone is
dependent on the nanostructures’ physicochemical properties,
namely on their size, charge, corona composition and decora-
tion with targeting ligands.32 These properties and consider-
ations regarding GFN biodistribution were recently analyzed
by our group and by other research teams (reviewed in detail
in ref. 32 and 69–71). In turn, the photothermal capacity of
GFN is influenced by the NIR absorption of each derivative
(reviewed in section 3.1), while the therapeutic outcome of the
combination PTT is affected by the local temperature variation
achieved upon irradiation (reviewed in section 3.2).
3.1. Photothermal capacity of GFN
The members of GFN have different capabilities to absorb the
NIR radiation, ultimately impacting their photothermal
capacity and hence their potential for combination PTT.
Due to its NIR absorption, GO can produce a temperature
increase upon interaction with NIR light. The attained temp-
erature variation is dependent on the concentration of GO and
on the laser related parameters (e.g. intensity, duration).23,72
The reduction of GO restores the nanostructures’ aromatic
lattice, thus improving their NIR absorption and photothermal
potential.32,34 In this regard, Yang et al. demonstrated that
rGO based materials can display a 3–4 fold higher NIR absorp-
tion than GO derivatives.34 Consequently, the GO derivatives
could produce a temperature increase to about 44 °C under
NIR laser irradiation, while the rGO based materials induced a
photoinduced heat to ≈58 °C (808 nm, 1 W cm−2, 5 min).34
However, the manipulation of rGO based materials is not
straightforward. The rGO derivatives can aggregate irreversibly
during the reduction phase, thus requiring additional proces-
sing steps.34,50 Furthermore, the use of rGO demands
additional purification routines to ensure the removal of the
reducing agents, some of which are cytotoxic.34,73 Due to these
reasons, GO derivatives are still widely explored in cancer PTT.
The other GFN can display an enhanced photothermal
capacity. GONR present a NIR absorption similar to that of GO
based materials.55 In contrast, rGONR based materials can
display a ≈2.4-fold higher absorption at 808 nm than rGO
derivatives.55 Such phenomenon was attributed to the higher
abundance of low-energy vibrational modes in rGONR arising
from their intrinsic shape.55 Due to their higher NIR absorp-
tion, the rGONR based materials could produce a temperature
increase up to ≈61 °C under NIR laser irradiation, while the
rGO derivatives only raised the temperature to ≈46 °C
(808 nm, 7.5 W cm−2, 10 min).55
Review Biomaterials Science


















































Akhavan et al. demonstrated that rGONM displays a 4.2-fold
higher NIR absorption than rGO based materials.57 A greater
restoration of rGONM aromatic lattice and/or a higher abun-
dance of low-energy vibrational modes in this nanomaterial
can explain its enhanced NIR absorption.55,57 Due to this fact,
rGONM can produce a photoinduced heat to ≈57 °C (808 nm,
0.1 W cm−2, 8 min).57 Under the same conditions, the rGO
based materials only produced a temperature increase to
about 42 °C.57
3.2. Effect of the temperature increase mediated by GFN
The local temperature increase mediated by GFN upon NIR
laser irradiation will dictate the therapeutic outcome of the
combination PTT. Depending on the temperature achieved,
the photoinduced heat mediated by GFN can induce irrevers-
ible or reversible damage on cells. In this context, achieving a
photoinduced heat to about 50 °C can per se induce irrevers-
ible damage on cells, causing protein denaturation, collapse of
cells’ membrane, and dysfunctions on the activity of enzymes
and mitochondria.74 These events ultimately lead to cells’
death by coagulative necrosis.74
On the other hand, a local temperature increase to about
41–45 °C can per se induce sub-lethal and reversible damage
on cells by compromising cells’ metabolism and DNA repair
mechanisms.74,75 Furthermore, this temperature range can
also sensitize cells to the action of other therapeutics or
enhance therapeutics’ efficacy, leading to an improved
outcome.75
Mild hyperthermia can increase the blood flow into the
tumor tissue, improving tissues’ oxygenation.75,76 Moreover,
this increased blood flow can also augment the amount of
GFN that reach the tumor zone (hyperthermia enhanced EPR
Fig. 2 Illustration of the vascular and cellular effects of GFN mediated photoinduced heat.
Biomaterials Science Review
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































effect).77 As a result of the mild hyperthermia, cells’ mem-
brane permeability is also affected.75,78 In this way, the temp-
erature increase produced by GFN upon NIR laser irradiation
can improve nanomaterials’ cellular uptake.40,72,79 The photo-
induced heat generated by GFN can also disrupt the endo-
somes/lysosomes, prompting the delivery of the loaded agents
to the cytoplasm.53,80 Additionally, the interaction of the GFN
with NIR light can trigger the intracellular release of the
loaded therapeutics.54 By taking advantage from these mecha-
nisms (illustrated in Fig. 2) and from the effects of the
hyperthermia per se, GFN mediated PTT can improve the thera-
peutic outcome of different types of therapies (reviewed in the
following sections).
4. PTT mediated by GFN in
combination with chemotherapy
The aromatic lattice of GFN allows the direct loading of che-
motherapeutics on their structure through hydrophobic–hydro-
phobic interactions and/or π–π stacking.81,82 In this way, GFN
can be explored to control the delivery of drugs to cancer cells.
Chen et al. demonstrated that the NIR light can trigger the
release of resveratrol from rGO based materials inside cancer
cells.54 By exposing cells to NIR light for 10 min, the intracellu-
lar release of this drug increased from about 3% to ≈30%.54
Such behavior can be attributed to the detachment of the drugs
from GFN due to the local temperature increase achieved upon
NIR laser irradiation.54,83 Additionally, the photoinduced heat
generated by both GO and rGO based materials can also disrupt
the endo/lysosomes,53,84 further contributing to the release of
the loaded drugs in the cytoplasm.
By taking advantage from these two phenomena and from
the cellular effects of the hyperthermia per se, GFN mediated
chemo-PTT can lead to improved therapeutic outcomes
(Tables 1 and 2). For instance, Thapa and co-workers verified
that the chemo-PTT mediated by folic acid-functionalized rGO
co-loaded with irinotecan and docetaxel could reduce MCF-7
cells’ viability to about 24%.81 In stark contrast, the sole appli-
cation of the dual drug loaded rGO based material (che-
motherapeutic effect) or the conjugation of the rGO based
material with NIR light (photothermal effect) only decreased
cells’ viability to about 64 and 84%, respectively.81 In another
work, Feng et al. verified that the delivery of doxorubicin
(DOX) through PEGylated pH-responsive GO to DOX-resistant
MCF-7 cells could reduce their viability to about 55%
(Fig. 3).82 In turn, the chemo-photothermal effect mediated by
the DOX loaded GFN reduced cells’ viability to about 21%,82
proving to be a promising agent for the elimination of drug-
resistant cancer cells.
The hyperthermia induced by GFN can also enhance nano-
structures’ ability to deliver drugs to the tumor tissue. In this
regard, Li et al. verified that the delivery of a platinum complex
by PEGylated GO would result in a platinum tumor accumu-
lation of 9.6 µg g−1 (Fig. 4).77 In contrast, mice treated with the


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































tumor uptake of 13.3 µg g−1.77 As a result, the chemo-PTT
mediated by platinum-PEG-GO complex induced tumors’ eradi-
cation while the sole application of chemotherapy (platinum or
platinum-PEG-GO complex) or PTT (PEG-GO + NIR) only led to
a reduction or inhibition of the tumors’ growth, respectively.77 A
similar observation was reported by Shi et al., which verified
that the DOX released in the tumor tissue of mice treated with a
DOX-GO based conjugate could be increased by about 1.65
times upon NIR laser irradiation.85
5. PTT mediated by GFN in
combination with photodynamic
therapy
GFN aromatic structure can incorporate photosensitizers for
application in combination photodynamic-PTT. For this
purpose, chlorin e6 (Ce6) and phthalocyanine derivatives have
been adsorbed on GFN surface by taking advantage from hydro-
phobic–hydrophobic interactions and/or π–π stacking.40,86
Furthermore, photosensitizers may also be included on GFN
through electrostatic interactions or covalent bonding.66,87
Ideally, the photosensitizers incorporated on GFN should
have a high absorption in the NIR region, allowing the NIR
radiation to excite both the photodynamic agent and the GFN
(photothermal agent).66 However, most of the photosensitizers
incorporated so far on GFN do not have a high NIR
absorption.40,87–89 In this way, the combination photo-
dynamic-PTT mediated by GFN commonly employs radiation
with a wavelength suitable for the photosensitizer (e.g. 660 nm
radiation for Ce6) and 808 nm radiation for the GFN40
(Tables 1 and 2).
The photoinduced heat generated by GFN can induce the
release of the loaded photosensitizers from GFN structure.88
This phenomenon has a great importance since GFN can
quench the reactive oxygen species (e.g. singlet oxygen) gener-
ated by the photosensitizers upon irradiation.86–88 In this way,
the NIR light induced release of the photodynamic agents,
from the structure of GFN, can potentially restore their activity.
Fig. 3 Properties of DOX loaded PEG functionalized pH-responsive GO. (a) Optical and infrared thermal images of water and PEG functionalized
pH-responsive GO upon exposure to NIR light (808 nm, 1 W cm−2, 5 min). (b) Temperature variation curves of PEG functionalized pH-responsive
GO upon NIR laser irradiation. (c) Chemo-PTT effect mediated by DOX loaded PEG functionalized pH-responsive GO towards DOX-resistant
MCF-7 cells (808 nm, 0.5 W cm−2, 5 min; with laser irradiation). DOX loaded PEG functionalized pH-responsive GO (NGO-PEG-DA/DOX), PEG
functionalized pH-responsive GO (NGO-PEG-DA). Copyright © 2014 by John Wiley & Sons, Inc. Reprinted from ref. 82 by permission of John Wiley
& Sons, Inc.
Biomaterials Science Review


















































Moreover, the temperature increase induced by GFN upon NIR
laser irradiation can improve the uptake of these nano-
materials by cells.40 In this regard, Tian et al. observed that the
intracellular delivery of Ce6 by PEGylated GO is improved by
2–3 fold upon NIR laser irradiation.40
In this way, the combination photodynamic-PTT mediated
by GFN can result in an enhanced therapeutic outcome
(Tables 1 and 2). Dos Santos et al. verified that the irradiation
of Pluronic F127 functionalized GO incorporating methylene
blue with 660 and 808 nm lights generates a combined photo-
dynamic–photothermal effect capable of ablating mice tumors
and of preventing metastasis in major organs.89 In contrast,
the sole application of the photodynamic (methylene blue
loaded GO based material + 660 nm radiation) and photother-
mal (methylene blue loaded GO based material + 808 nm radi-
ation) treatments only induced a slight reduction in the
tumor’s growth and did not inhibit the occurrence of metas-
tases.89 In another work, the combined photodynamic-PTT
mediated by rGO incorporating a PEGylated Ru(II) complex
(photosensitizer) also induced a superior therapeutic outcome
when compared to the sole application of PTT (PEG-Ru(II)/rGO
plus 808 nm radiation) or photodynamic therapy (PEG-Ru(II)/
rGO plus 450 nm radiation).88
6. PTT mediated by GFN in
combination with gene therapy
GFN can be modified with polycations to enable their appli-
cation in gene delivery. In this regard, GFN functionalized with
poly(ethylenimine) (PEI), poly(allylamine hydrochloride) (PAH)
and chitosan can form complexes with pDNA or siRNA through
electrostatic interactions established between the polycations
and the negatively charged groups of the genetic material.72,90,91
The photoinduced heat generated by GFN can further
enhance their gene delivery capabilities.72,80 In fact, the trans-
fection efficiency mediated by GFN can be augmented by increas-
ing cells’ exposure to the NIR light.80 For instance, Feng et al. ver-
ified that the PEI-PEG-GO mediated transfection of cancer cells
with EGFP can be increased by up to ≈10 times upon NIR laser
irradiation.72 In other work, the photothermal transfection
efficiency of PEG-PEI-rGO was also 2–3 times greater than that
attained without the use of NIR light.80 Furthermore, the conju-
gation of NIR light and GFN incorporating siRNA can also result
in an improved gene silencing (Fig. 5).72
The photothermally enhanced gene transfection/silencing
mediated by GFN can be explained by the improved uptake of
Fig. 4 In vivo outcome of the chemo-PTT mediated by platinum-PEG-GO complex. (A) Relative tumor volume changes of mice exposed to
different treatments. Photos of the tumors (B) and mice (C) at the end point of the study. (D) Pt content in mice’s major organs and tumor. (E)
Hematoxylin and eosin staining of the mice’s tumor tissue. Cisplatin (Pt(II)), NIR light irradiation (785 nm, 1.5 W cm−2, 3 min; +NIR), Non-irradiated
(-NIR), PEG-GO (PEG-NGO), Phosphate Buffered Saline (PBS), Platinum-PEG-GO complex (PEG-NGO-Pt). Reprinted from ref. 77, Copyright (2015),
with permission from Elsevier.
Review Biomaterials Science


















































these nanomaterials by cells achieved after NIR laser
irradiation.72 Moreover, the photoinduced heat generated by
both GO and rGO based materials can also induce the escape
of these materials from the endosomes, further contributing
to their improved gene transfection capabilities.80,92
Importantly, both of these two phenomena appear to be
mediated by the site-specific temperature increase mediated
by GFN upon exposure to NIR light, since the direct heating of
the cells at 43 °C did not result in an enhanced cellular
uptake/improved endosomal escape.72,80
In this way, the combination of the gene delivery and PTT
mediated by GFN can result in an improved therapeutic
outcome (Table 1). Yin et al. studied the therapeutic capacity
of PAH/Folic acid-PEG-GO complexed with siRNA targeting the
HDAC1 and K-Ras genes.90 When compared to mice treated
with saline (control), the combined effect of the GO based
material and NIR light (PTT) was able to reduce mice tumor’s
weight by ≈38%.90 On the other hand, the siRNA-GO based
complex (gene delivery) induced a tumor weight reduction of
≈78%.90 In stark contrast, the combination of the siRNA-GO
based complex with NIR light reduced mice tumor’s weight by
≈95%,90 thereby confirming the superior efficacy of the GFN
photothermally enhanced gene delivery.
7. PTT mediated by GFN in
combination with radiotherapy
The combination of GFN mediated PTT with radiotherapy is
an emergent but promising approach. For this type of appli-
cation, radionuclides can be labeled onto GFN, enabling
internal radiotherapy.62 In this regard, Chen et al. labelled
PEGylated rGO with 131I using the chloramine-T oxidation
method.62 On the other hand, radiosensitizers such as
5-iodo-2′-deoxyuridine (IUdR) or bismuth heteropolytungstate
(BiP5W30) can also be incorporated on GFN.
76,93 These high-Z
structures have an X-ray dose enhancement effect on cells,
leading to an improved external radiotherapy.94
The temperature variation induced by GFN upon NIR
irradiation can trigger the release of the loaded radiosensiti-
zers.93 For instance, such phenomenon takes an important
role for IUdR since this thymidine analog is incorporated on
DNA.93 Moreover, GFN photoinduced heat can improve
tumors’ oxygenation,76 sensitizing cancer cells to radiation-
induced damage.
In this way, the application of GFN mediated radio-PTT can
lead to improved therapeutic outcomes (Tables 1 and 2). Zhou
and co-workers verified that poly(vinyl pyrrolidone)/BiP5W30-
rGO hybrids in combination with NIR light plus X-rays could
induce a tumor growth inhibition ratio of ≈98%.76 In contrast,
the effect of the hybrids plus NIR light or the hybrids plus
X-rays only prompted tumor growth inhibition ratios of about
66 and 81%, respectively.76 The sole application of the X-rays
only led to a ≈39% inhibition ratio.76 In another work, Chen
et al. reported that the radio-PTT mediated by 131I labeled
PEGylated rGO could induce tumor’s ablation in 4 out of 5 mice
(Fig. 6).62 On the other hand, GFN mediated internal radiother-
apy (131I-PEG-rGO) and GFN mediated PTT (PEG-rGO + NIR)
only induced a reduction of the tumors’ growth.62
8. PTT mediated by GFN in
combination with immunotherapy
Combining GFN mediated PTT with immunotherapy holds a
great potential for cancer treatment. This pioneering approach
Fig. 5 Improved uptake and gene silencing mediated by PEI-PEG-GO
under NIR laser irradiation. (a) Photothermally enhanced uptake of
PEI-PEG-GO complexed with 6-carboxyfluorescein labelled siRNA by
MDA-MB-435s cells. Plk1 mRNA (b) and protein (c) levels after treatment
with PEI-PEG-GO complexed with Plk1 siRNA plus NIR light.
Lipofectamine 2000 incorporating siPlk1 (Lipo-siPlk1), NIR light
irradiation (808 nm, 0.5 W cm−2, 20 min; with irradiation), PEI-PEG-GO
(NGO-PEG-PEI), siRNA targeting Plk1 (siPlk1), siRNA containing a scram-
ble sequence (siN.C.). Copyright © 2013 by John Wiley & Sons, Inc.
Reprinted from ref. 72 by permission of John Wiley & Sons, Inc.
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Fig. 6 In vivo outcome of the radio-PTT mediated by 131I labeled PEGylated rGO. (a) Infrared thermal images of mice treated with 131I labeled
PEGylated rGO in conjugation with NIR light irradiation. (b) Relative tumor volume changes of mice exposed to different treatments and (c) respect-
ive photos of the tumors at the end point of the study. (d) Tunnel staining of the mice’s tumor tissue. 131I labeled PEGylated rGO (131I-RGO-PEG), NIR
light irradiation (808 nm, 0.2 W cm−2, 20 min; +laser), PBS (Control), PEGylated rGO (RGO-PEG). Reprinted from ref. 62, Copyright (2015), with per-
mission from Elsevier.
Fig. 7 In vivo outcome of the immuno-PTT mediated by CpG ODNs/PEI-PEG-GO nanocomplex. (a) Schematic representation of the combination
immuno-PTT. (b) Infrared thermal images of mice treated CpG ODNs/PEI-PEG-GO nanocomplex plus NIR light irradiation. (c) Relative tumor volume
and body weight (d) changes of mice exposed to different treatments. Hematoxylin and eosin staining of the mice’s major organs after treatment
with (e) PBS plus NIR radiation, (f ) PEI-PEG-GO, (g) CpG ODNs, (h) CpG ODNs/PEI-PEG-GO, (i) PEI-PEG-GO plus NIR radiation and ( j) CpG ODNs/
PEI-PEG-GO plus NIR radiation. CpG ODNs (CpG), CpG ODNs/PEI-PEG-GO nanocomplex (GO-PEG-PEI-CpG), NIR radiation (808 nm, 2 W cm−2,
5 min; +NIR), PEI-PEG-GO (GO-PEG-PEI). Reprinted from ref. 79, Copyright (2014), with permission from Elsevier.
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was reported by Tao and co-workers which incorporated un-
methylated cytosine-phosphate-guanine oligodeoxynucleotides
(immunostimulatory molecules; CpG ODNs) on PEI-PEG-GO
through electrostatic interactions.79
The authors verified that the uptake of the CpG ODNs/
PEI-PEG-GO complex by macrophages cells could be increased
upon NIR laser irradiation.79 Moreover, the combination of the
CpG ODNs/GFN nanocomplex with NIR light augmented
macrophages’ TNF-α and IL-6 secretions by about 2.2- and 1.8-
fold, respectively.79 Such enhanced immunogenicity is likely to
result from the photothermally enhanced cellular uptake of
the nanocomplex.79 In vivo, mice treated with the GFN
mediated PTT (PEI-PEG-GO + NIR light) or with the GFN
mediated immunotherapy (CpG ODNs/PEI-PEG-GO nano-
complex) just presented a ≈50 or 38% inhibition of the
tumor’s growth, respectively (Fig. 7).79 In turn, the tumors of
mice treated with the CpG ODNs/PEI-PEG-GO nanocomplex
plus NIR radiation displayed a 91% growth inhibition, corro-
borating the improved therapeutic outcome arising from GFN
mediated immuno-PTT.79
9. Conclusion and outlook
The combination of GFN mediated PTT with other therapeutic
modalities has been showing promising results in cancer treat-
ment. Among the different GFN, GO and rGO based materials
have been the most explored for this therapeutic approach.
The wide application of GO and rGO in combination PTT
could be explained by their simpler synthesis when compared
to the other GFN. On the other hand, the enhanced photother-
mal potential displayed by rGONR and rGONM should motiv-
ate their investigation in combination PTT.
Furthermore, the analysis of the mechanisms involved in
GFN mediated combination PTT revealed that the improved
outcome arising from this therapeutic modality seems to be
mainly related to the (i) photothermally enhanced cellular
uptake, (ii) photothermally triggered compound release/endo-
somal-escape, and (iii) combined effect of the hyperthermia
per se with the other therapies.
Among the different combination approaches, the conju-
gation of GFN mediated PTT with chemo- and photodynamic-
therapies was by far the most explored by researchers (Fig. 8).
Such could be related to the fact that as-synthesized GFN can
directly incorporate chemotherapeutics/photosensitizers on
their structure through hydrophobic–hydrophobic interactions
and/or π–π stacking. Moreover, some reports also revealed that
GFN mediated chemo-PTT and photodynamic-PTT were able
to induce the complete eradication of mice’s tumor, disclosing
their high therapeutic efficacy (Fig. 8).
Regarding the combination of GFN mediated PTT with gene-,
radio- and immuno-therapies, the few studies on these modal-
ities revealed promising results. Nevertheless, the therapeutic
capacity of these emergent combination strategies is yet insuffi-
ciently explored, and thus should be further investigated.
Overall, GFN mediated PTT holds a great potential for improv-
ing the efficacy of different types of therapies, which should
motivate their continuous application for cancer treatment and
investigation in the context of other diseases.
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